

Atty. Docket No.: P65141US0
Serial No.: 09/508,095

- P2
Conclude*
- B0 represents the germ count obtained in the control incubation without active substances;
 - EW represents the germ count obtained upon 16 hours of incubation of *E. coli* in 3 g/l tryptic soy broth in the presence of the peptides in a concentration of 200 µg/ml;
 - EO represents the germ count obtained in the control incubation without active substances; and
 - isolation of the peptides contained in this fraction.

17. A method of using the peptide of claim 13 comprising orally administering the peptide to an individual to selectively promote growth of bifidobacteria, or selectively inhibit the growth of non-bifidobacteria, in the digestive tract.

Add E2

REMARKS

The specification is amended, hereby, in order to insert sequence identifiers. The requisite marked up version is attached, hereto.

Claim 13-17 replace claims 6, 7, 8, 9, and 12, respectively, in order to insert sequence identifiers (claim 14) and to, otherwise, address the issues raised in the Office Action.

Applicants request reconsideration of all the rejections and objections of record in view of the instant amendments to the specification and claims. It is submitted that all the rejections and objections of record are overcome by the instant amendment.

MAR. 24. 2003 11:36PM

JACOBSON, HOLMAN

NO. 856 P. 9/11


Atty. Docket No.: P65141US0
Serial No.: 09/508,095

Favorable action is requested.

Respectfully submitted,

JACOBSON HOLMAN PLLC

By


William E. Player

Registration No. 31,409

400 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 638-6666
Atty. Docket No.: P65141US0
Date: March 24, 2003
WEP/rdt
R:\vthomas\2003\MARCH\P65141amd.wpd

Atty. Docket No.: P65141US0
 Serial No.: 09/508,095

Marked up version of amendments to the specification
IN THE SPECIFICATION

Rewrite page 3 (amended), lines 6-last line, as:

Preferably, peptides are used which have the following amino acid sequences:

R₁-EQLLRLKK-R₂ (SEQ ID NO: 1), R₁-YLEQLLRLKKY-R₂ (SEQ ID NO: 2),
 R₁-NRQRNILR-R₂ (SEQ ID NO: 3), R₁-YMNGMNRQRNILR-R (SEQ ID NO: 4),
 R₁-FQWQRNMRK-R₂ (SEQ ID NO: 5), R₁-HTGLRRTA-R₂ (SEQ ID NO: 6),
 R₁-FTAIQNLRK-R₂ (SEQ ID NO: 7), R₁-EVAARARVWW-R₂ (SEQ ID NO: 8),
 R₁-WQRNMRKV-R₂ (SEQ ID NO: 9), R₁-LARTLKRLK-R₂ (SEQ ID NO: 10),
 R₁-YKQKVEKV-R₂ (SEQ ID NO: 11), R₁-LVRYTKKV-R₂ (SEQ ID NO: 12),
 R₁-KYLYEIARR-R₂ (SEQ ID NO: 13), R₁-ARRARVWWCAVG-R₂ (SEQ ID NO: 14),
 R₁-ARRARVWWCAVGE-R₂ (SEQ ID NO: 16), R₃-CIAL-R₄ (SEQ ID NO: 15),
 R₃-CIAL-R₄ (SEQ ID NO: 15),
 R₁-YQRRPAIAINNPYVPRTYYANPAVVRPHAQIPQRQYLPNSHPPTVRRPNLHPSF-R₂,
(SEQ ID NO: 17)
 R₁-GRRRSVQWCTVSQPEATKFQWQRNMRRVRGPPVSCIKRDSPICQCIQA-R₂
(SEQ ID NO: 18),
 R₁-GRRRSVQWCAVSQPEATKCFQWQRNMRRKVRGPPVSCIKRDSPICQCIQA-R₂,
(SEQ ID NO: 19),
 R₁-GRRRSVQWCAVSQPEATKCFQWQRNMRRKVRGPPVSCIKRDSPICQCIQA-R₂,
(SEQ ID NO: 20),
 R₁-VYQHQKAMPKPWIOPKTKVIPYVRYL-R₂ (SEQ ID NO: 21),
 R₁-ARRARVWWAAVG-R₂,
(SEQ ID NO: 22),
 R₁-CAVGGGCIAL-R₂ (SEQ ID NO: 23),

Atty. Docket No.: P65141US0
Serial No.: 09/508,095

R₁-RHTRKYWCRQGARGGCITL-R₂ (SEQ ID NO: 24),

wherein

R₁, R₂, R₃, and R₄ are optionally present.

R₁, R₃ independently represents [NH₂] an amino acid[,] or a peptide containing up to 100 amino acids, and

R₂, R₄ independently represents [COOH] CONH₂[.] an amino acid, or a peptide containing up to 100 amino acids;

and the amided acetylated, sulfated, phosphorylated, glycosylated, oxidized derivatives or fragments thereof having bifidogenic properties.